Solicitation of Nominations for Three Organizations To Serve as Non-Voting Liaison Representatives to the Chronic Fatigue Syndrome Advisory Committee, 19740-19742 [2017-08383]
Download as PDF
19740
Federal Register / Vol. 82, No. 81 / Friday, April 28, 2017 / Notices
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
responses per
respondent
Number of
respondents
Form name
Total
responses
Average
burden per
response (in
hours)
Total burden
hours
Account Creation ...................................................................................................
Complete Profile ....................................................................................................
15,600
9,400
1
1
15,600
9,400
.08
1
1,248
9,400
Total ...............................................................................................................
*15,600
—
15,600
—
10,648
* The 9,400 respondents who complete their profiles are a subset of the 15,600 respondents who create accounts.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2017–08584 Filed 4–27–17; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
[Document Identifier 0990–0421–60D]
Agency Information Collection
Activities; Proposed Collection; Public
Comment Request
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
In compliance with section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human Services, announces plans
to submit an Information Collection
Request (ICR), described below, to the
Office of Management and Budget
(OMB). The ICR is for extending the use
of the approved information collection
assigned OMB control number 0990–
0421, which expires on July 31, 2017.
Prior to submitting the ICR to OMB, OS
seeks comments from the public
regarding the burden estimate, below, or
any other aspect of the ICR.
SUMMARY:
Comments on the ICR must be
received on or before June 27, 2017.
ADDRESSES: Submit your comments to
Information.CollectionClearance
@hhs.gov or by calling (202) 795–7714.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the
document identifier 0990–0421–60D for
reference.
Information Collection Request Title:
ASPE Generic Clearance for the
Collection of Qualitative Research and
Assessment.
OMB No.: 0990–0421.
Abstract: The Office of the Assistant
Secretary for Planning and Evaluation
(ASPE) is requesting an extension for
their generic clearance for purposes of
conducting qualitative research. ASPE
conducts qualitative research to gain a
better understanding of emerging health
policy issues, develop future intramural
and extramural research projects, and to
ensure HHS leadership, agencies and
offices have recent data and information
to inform program and policy decisionmaking. ASPE is requesting approval for
at least four types of qualitative
research: (a) Interviews, (b) focus
groups, (c) questionnaires, and (d) other
qualitative methods. ASPE’s mission is
to advise the Secretary of the
Department of Health and Human
Services on policy development in
DATES:
health, disability, human services, data,
and science, and provides advice and
analysis on economic policy. ASPE
leads special initiatives, coordinates the
Department’s evaluation, research and
demonstration activities, and manages
cross-Department planning activities
such as strategic planning, legislative
planning, and review of regulations.
Integral to this role, ASPE will use this
mechanism to conduct qualitative
research, evaluation, or assessment,
conduct analyses, and understand
needs, barriers, or facilitators for HHSrelated programs.
ASPE is requesting comment on the
burden for qualitative research aimed at
understanding emerging health and
human services policy issues. The goal
of developing these activities is to
identify emerging issues and research
gaps to ensure the successful
implementation of HHS programs. The
participants may include health and
human services experts; national, state,
and local health or human services
representatives; public health, human
services, or healthcare providers; and
representatives of other health or human
services organizations. The increase in
burden from 747 in 2014 to 1,300
respondents in 2017 reflects an increase
in the number of research projects
conducted over the estimate in 2014.
ESTIMATED ANNUALIZED BURDEN TABLE
Form
Number of
respondents
Number of
responses per
respondent
Average
burden
hours per
response
Total burden
hours
Health Policy Stakeholder .................................
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Type of respondent
Qualitative Research .........................................
1,300
1
1
1,300
OS specifically requests comments on
(1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
VerDate Sep<11>2014
17:38 Apr 27, 2017
Jkt 241001
technology to minimize the information
collection burden.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Terry S. Clark,
Asst Information Collection Clearance
Officer.
Solicitation of Nominations for Three
Organizations To Serve as Non-Voting
Liaison Representatives to the Chronic
Fatigue Syndrome Advisory
Committee
[FR Doc. 2017–08599 Filed 4–27–17; 8:45 am]
BILLING CODE 4150–05–P
PO 00000
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
AGENCY:
Frm 00089
Fmt 4703
Sfmt 4703
E:\FR\FM\28APN1.SGM
28APN1
Federal Register / Vol. 82, No. 81 / Friday, April 28, 2017 / Notices
ACTION:
Notice.
The Chronic Fatigue
Syndrome Advisory Committee
(CFSAC) is one of the federal advisory
committees for which the Department of
Health and Human Services (HHS)
provides management support. The
Office of the Assistant Secretary for
Health (OASH), a staff division in the
Office of the Secretary, HHS, is assigned
responsibility to provide management
support for CFSAC activities. The
CFSAC is authorized to have three nonvoting liaison representative positions.
The organizations designated to fill
these positions will be selected from
those concerned with myalgic
encephalomyelitis/chronic fatigue
syndrome (ME/CFS). The Designated
Federal Officer (DFO) for CFSAC will
select the organizations from which the
representative will be selected to fill
these vacant positions. The
representatives selected to fill these
positions will serve a two-year term as
a non-voting liaison representative.
Details of nomination requirements are
provided below.
DATES: Nominations must be received
no later than 5 p.m. ET on May 30,
2017, at the address listed below.
ADDRESSES: All nominations should be
sent to Commander Gustavo Ceinos,
Designated Federal Officer, Chronic
Fatigue Syndrome Advisory Committee,
Office on Women’s Health, Department
of Health and Human Services, 200
Independence Avenue SW., Room
728F.6, Washington, DC 20201.
Nomination materials, including
attachments, may be submitted
electronically to cfsac@hhs.gov.
FOR FURTHER INFORMATION CONTACT:
Commander Gustavo Ceinos, Designated
Federal Officer, Chronic Fatigue
Syndrome Advisory Committee, Office
on Women’s Health, Department of
Health and Human Services, 200
Independence Avenue SW., Room
728F.6, Washington, DC 20201. The
telephone number is: 202–401–9545.
Inquiries can be sent to cfsac@hhs.gov.
SUPPLEMENTARY INFORMATION: CFSAC
was established on September 5, 2002.
The purpose of the CFSAC is to provide
advice and recommendations to the
Secretary of HHS, through the Assistant
Secretary for Health, on issues related to
ME/CFS. CFSAC advises and makes
recommendations on a broad range of
topics including: (1) Opportunities to
improve knowledge and research about
the epidemiology, etiologies, biomarkers
and risk factors for ME/CFS; (2) research
on the diagnosis, treatment, and
management of ME/CFS and potential
impact of treatment options; (3)
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:38 Apr 27, 2017
Jkt 241001
strategies to inform the public, health
care professionals, and the biomedical
academic and research communities
about ME/CFS advances; (4)
partnerships to improve the quality of
life of ME/CFS patients; and (5)
strategies to insure that input from ME/
CFS patients and caregivers is
incorporated into HHS policy and
research. Management and support
services for Committee activities are
provided by staff from the HHS Office
on Women’s Health, within the OASH.
The CFSAC charter is available at
https://www.hhs.gov/ash/advisorycommittees/cfsac/about-cfsac/charter/
index.html.
CFSAC meetings are held not less
than two times per year. The CFSAC
membership consists of 13 voting
members, including the Chair. The
voting members are composed of seven
biomedical research scientists with
demonstrated expertise in biomedical
research applicable to ME/CFS; three
individuals with expertise in health care
delivery, private health care services or
insurers, or voluntary organizations
concerned with the problems of
individuals with ME/CFS, and three are
either patients or caregivers affected by
ME/CFS.
CFSAC also includes eight non-voting
ex-officio representatives from the
Agency for Healthcare Research and
Quality, Centers for Disease Control and
Prevention, Food and Drug
Administration, Health Resources and
Services Administration, National
Institutes of Health, Social Security
Administration, U.S. Department of
Veteran Affairs, and the Department of
Defense.
In 2012, the CFSAC structure was
expanded to include three non-voting
liaison representative positions. These
positions are occupied by
representatives from organizations that
are concerned with ME/CFS. The terms
of the current non-voting liaison
representative positions expire in May.
The selected organizations will occupy
the position for a two-year term.
Nominations: The OASH is requesting
nominations of organizations to fill the
three non-voting liaison representative
positions for the CFSAC. The
organizations will be selected by the
DFO or designee.
Selection of the three organizations
which will serve as non-voting liaison
representatives will be based on the
organizations’ qualifications to
contribute to the accomplishment of the
CFSAC mission, as described in the
Committee charter. In selecting the
organizations to be considered for these
positions, the OASH will give close
attention to equitable geographic
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
19741
distribution and give priority to U.S.chartered 501(c)(3) organizations that
operate within the United States and
have membership with demonstrated
expertise in ME/CFS and related
research, clinical services, or advocacy
and outreach on issues concerning ME/
CFS.
The individuals designated by the
selected organizations to serve as the
official liaison representative will
perform the associated duties without
compensation, and will not receive per
diem or reimbursement for travel
expenses. The organizations selected
will cover expenses for their designated
representative to attend, at a minimum,
one in-person CFSAC meeting per year
during the designated term of
appointment.
To qualify for consideration of
selection to the Committee, an
organization should submit the
following items:
(1) A statement of the organization’s
history, mission, and focus, including
information that demonstrates the
organization’s experience and expertise
in ME/CFS and related research, clinical
services, or advocacy and outreach on
issues of ME/CFS, as well as expert
knowledge of the broad issues and
topics pertinent to ME/CFS. This
information should demonstrate the
organization’s proven ability to work
and communicate with the ME/CFS
patient and advocacy community, and
other public/private organizations
concerned with ME/CFS, including
public health agencies at the federal,
state, and local levels.
(2) two to four letters of
recommendation that clearly state why
the organization is qualified to serve on
CFSAC in a liaison representative
position. These letters should be from
individuals who are not part of the
organization.
(3) A statement that the organization
is willing to serve as a non-voting
liaison representative of the Committee
and will cover expenses for their
representative to attend in-person, at a
minimum, one CFSAC meeting per year
in Washington, DC, during the
designated term of appointment.
(4) A current financial disclosure
statement (or annual report)
demonstrating the organization’s ability
to cover expenses for its representative
to attend in-person, at a minimum, one
CFSAC meeting per year in Washington,
DC, during the term of appointment.
Submitted nominations must include
these critical elements in order for the
organization to be considered for one of
the liaison representative positions.
Nomination materials should be
typewritten, using a 12-point font and
E:\FR\FM\28APN1.SGM
28APN1
19742
Federal Register / Vol. 82, No. 81 / Friday, April 28, 2017 / Notices
double-spaced. All nomination
materials should be submitted
(postmarked or received) by May 30,
2017.
Electronic submissions: Nomination
materials, including attachments, may
be submitted electronically to cfsac@
hhs.gov. An email from the CFSAC
Support Team will be sent to the
nominating organization and/or
nominator to confirm receipt of the
nomination. If the email confirmation is
not received within two working days,
please call 202–690–7650. Telephone
and facsimile submissions cannot be
accepted.
Regular, Express, or Overnight Mail:
Written documents may be submitted to
the following addressee only:
Commander Gustavo Ceinos, Designated
Federal Officer, CFSAC, Office on
Women’s Health, Department of Health
and Human Services, 200 Independence
Avenue SW., Room 728F.6, Washington,
DC 20201.
HHS makes every effort to ensure that
the membership of federal advisory
committees is fairly balanced in terms of
points of view represented. Every effort
is made to ensure that a broad
representation of geographic areas, sex,
ethnic and minority groups, and people
with disabilities are given consideration
for membership on federal advisory
committees. Selection of the represented
organizations shall be made without
discrimination against the composition
of an organization’s membership on the
basis of age, sex, race, ethnicity, sexual
orientation, disability, and cultural,
religious, or socioeconomic status.
Authority: 42 U.S.C. 217a, section 222 of
the Public Health Service (PHS) Act, as
amended. The Committee is governed by the
provisions of the Federal Advisory
Committee Act, as amended (5 U.S.C. App 2),
which sets forth standards for the formation
and use of advisory committees.
Dated: April 18, 2017.
Nicole Greene,
Acting Director, Office on Women’s Health.
[FR Doc. 2017–08383 Filed 4–27–17; 8:45 am]
BILLING CODE 4150–42–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
asabaliauskas on DSK3SPTVN1PROD with NOTICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
VerDate Sep<11>2014
17:38 Apr 27, 2017
Jkt 241001
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Peer-Review of (SCORE) Advancement
Award.
Date: June 23, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Cambria Suites Rockville, I Helen
Heneghan Way, Rockville, MD 20850.
Contact Person: Manas Chattopadhyay,
Ph.D., Scientific Review Officer, Office of
Scientific Review, National Institute of
General Medical Sciences, National Institutes
of Health, Building 45, Room 3An12N, 45
Center Drive, Bethesda, MD 20892, 301–827–
5320, manasc@mail.nih.gov.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Centers of Biomedical Research
Excellence (COBRE) (P20).
Date: June 29, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Cambria Suites Rockville, 1 Helen
Heneghan Way, Rockville, MD 20850.
Contact Person: Shinako Takada, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3AN18, Bethesda, MD
20892–6200, 301–402–9448,
shinako.takada@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859,
Biomedical Research and Research Training,
National Institutes of Health, HHS)
Dated: April 25, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–08629 Filed 4–27–17; 8:45 am]
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Interventions and Biomarkers Special
Emphasis Panel.
Date: May 24, 2017.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Marcy Ellen Burstein,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6143, MSC 9606,
Bethesda, MD 20892–9606, 301–443–9699,
bursteinme@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Confirmatory Efficacy Clinical Trials of NonPharmacological Interventions for Mental
Disorders.
Date: May 24, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Marcy Ellen Burstein,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6143, MSC 9606,
Bethesda, MD 20892–9606, 301–443–9699,
bursteinme@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: April 25, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–08630 Filed 4–27–17; 8:45 am]
BILLING CODE 4140–01–P
Frm 00091
Fmt 4703
Sfmt 9990
E:\FR\FM\28APN1.SGM
28APN1
Agencies
[Federal Register Volume 82, Number 81 (Friday, April 28, 2017)]
[Notices]
[Pages 19740-19742]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08383]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Solicitation of Nominations for Three Organizations To Serve as
Non-Voting Liaison Representatives to the Chronic Fatigue Syndrome
Advisory Committee
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
[[Page 19741]]
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Chronic Fatigue Syndrome Advisory Committee (CFSAC) is one
of the federal advisory committees for which the Department of Health
and Human Services (HHS) provides management support. The Office of the
Assistant Secretary for Health (OASH), a staff division in the Office
of the Secretary, HHS, is assigned responsibility to provide management
support for CFSAC activities. The CFSAC is authorized to have three
non-voting liaison representative positions. The organizations
designated to fill these positions will be selected from those
concerned with myalgic encephalomyelitis/chronic fatigue syndrome (ME/
CFS). The Designated Federal Officer (DFO) for CFSAC will select the
organizations from which the representative will be selected to fill
these vacant positions. The representatives selected to fill these
positions will serve a two-year term as a non-voting liaison
representative. Details of nomination requirements are provided below.
DATES: Nominations must be received no later than 5 p.m. ET on May 30,
2017, at the address listed below.
ADDRESSES: All nominations should be sent to Commander Gustavo Ceinos,
Designated Federal Officer, Chronic Fatigue Syndrome Advisory
Committee, Office on Women's Health, Department of Health and Human
Services, 200 Independence Avenue SW., Room 728F.6, Washington, DC
20201. Nomination materials, including attachments, may be submitted
electronically to cfsac@hhs.gov.
FOR FURTHER INFORMATION CONTACT: Commander Gustavo Ceinos, Designated
Federal Officer, Chronic Fatigue Syndrome Advisory Committee, Office on
Women's Health, Department of Health and Human Services, 200
Independence Avenue SW., Room 728F.6, Washington, DC 20201. The
telephone number is: 202-401-9545. Inquiries can be sent to
cfsac@hhs.gov.
SUPPLEMENTARY INFORMATION: CFSAC was established on September 5, 2002.
The purpose of the CFSAC is to provide advice and recommendations to
the Secretary of HHS, through the Assistant Secretary for Health, on
issues related to ME/CFS. CFSAC advises and makes recommendations on a
broad range of topics including: (1) Opportunities to improve knowledge
and research about the epidemiology, etiologies, biomarkers and risk
factors for ME/CFS; (2) research on the diagnosis, treatment, and
management of ME/CFS and potential impact of treatment options; (3)
strategies to inform the public, health care professionals, and the
biomedical academic and research communities about ME/CFS advances; (4)
partnerships to improve the quality of life of ME/CFS patients; and (5)
strategies to insure that input from ME/CFS patients and caregivers is
incorporated into HHS policy and research. Management and support
services for Committee activities are provided by staff from the HHS
Office on Women's Health, within the OASH. The CFSAC charter is
available at https://www.hhs.gov/ash/advisory-committees/cfsac/about-cfsac/charter/.
CFSAC meetings are held not less than two times per year. The CFSAC
membership consists of 13 voting members, including the Chair. The
voting members are composed of seven biomedical research scientists
with demonstrated expertise in biomedical research applicable to ME/
CFS; three individuals with expertise in health care delivery, private
health care services or insurers, or voluntary organizations concerned
with the problems of individuals with ME/CFS, and three are either
patients or caregivers affected by ME/CFS.
CFSAC also includes eight non-voting ex-officio representatives
from the Agency for Healthcare Research and Quality, Centers for
Disease Control and Prevention, Food and Drug Administration, Health
Resources and Services Administration, National Institutes of Health,
Social Security Administration, U.S. Department of Veteran Affairs, and
the Department of Defense.
In 2012, the CFSAC structure was expanded to include three non-
voting liaison representative positions. These positions are occupied
by representatives from organizations that are concerned with ME/CFS.
The terms of the current non-voting liaison representative positions
expire in May. The selected organizations will occupy the position for
a two-year term.
Nominations: The OASH is requesting nominations of organizations to
fill the three non-voting liaison representative positions for the
CFSAC. The organizations will be selected by the DFO or designee.
Selection of the three organizations which will serve as non-voting
liaison representatives will be based on the organizations'
qualifications to contribute to the accomplishment of the CFSAC
mission, as described in the Committee charter. In selecting the
organizations to be considered for these positions, the OASH will give
close attention to equitable geographic distribution and give priority
to U.S.-chartered 501(c)(3) organizations that operate within the
United States and have membership with demonstrated expertise in ME/CFS
and related research, clinical services, or advocacy and outreach on
issues concerning ME/CFS.
The individuals designated by the selected organizations to serve
as the official liaison representative will perform the associated
duties without compensation, and will not receive per diem or
reimbursement for travel expenses. The organizations selected will
cover expenses for their designated representative to attend, at a
minimum, one in-person CFSAC meeting per year during the designated
term of appointment.
To qualify for consideration of selection to the Committee, an
organization should submit the following items:
(1) A statement of the organization's history, mission, and focus,
including information that demonstrates the organization's experience
and expertise in ME/CFS and related research, clinical services, or
advocacy and outreach on issues of ME/CFS, as well as expert knowledge
of the broad issues and topics pertinent to ME/CFS. This information
should demonstrate the organization's proven ability to work and
communicate with the ME/CFS patient and advocacy community, and other
public/private organizations concerned with ME/CFS, including public
health agencies at the federal, state, and local levels.
(2) two to four letters of recommendation that clearly state why
the organization is qualified to serve on CFSAC in a liaison
representative position. These letters should be from individuals who
are not part of the organization.
(3) A statement that the organization is willing to serve as a non-
voting liaison representative of the Committee and will cover expenses
for their representative to attend in-person, at a minimum, one CFSAC
meeting per year in Washington, DC, during the designated term of
appointment.
(4) A current financial disclosure statement (or annual report)
demonstrating the organization's ability to cover expenses for its
representative to attend in-person, at a minimum, one CFSAC meeting per
year in Washington, DC, during the term of appointment.
Submitted nominations must include these critical elements in order
for the organization to be considered for one of the liaison
representative positions.
Nomination materials should be typewritten, using a 12-point font
and
[[Page 19742]]
double-spaced. All nomination materials should be submitted (postmarked
or received) by May 30, 2017.
Electronic submissions: Nomination materials, including
attachments, may be submitted electronically to cfsac@hhs.gov. An email
from the CFSAC Support Team will be sent to the nominating organization
and/or nominator to confirm receipt of the nomination. If the email
confirmation is not received within two working days, please call 202-
690-7650. Telephone and facsimile submissions cannot be accepted.
Regular, Express, or Overnight Mail: Written documents may be
submitted to the following addressee only: Commander Gustavo Ceinos,
Designated Federal Officer, CFSAC, Office on Women's Health, Department
of Health and Human Services, 200 Independence Avenue SW., Room 728F.6,
Washington, DC 20201.
HHS makes every effort to ensure that the membership of federal
advisory committees is fairly balanced in terms of points of view
represented. Every effort is made to ensure that a broad representation
of geographic areas, sex, ethnic and minority groups, and people with
disabilities are given consideration for membership on federal advisory
committees. Selection of the represented organizations shall be made
without discrimination against the composition of an organization's
membership on the basis of age, sex, race, ethnicity, sexual
orientation, disability, and cultural, religious, or socioeconomic
status.
Authority: 42 U.S.C. 217a, section 222 of the Public Health
Service (PHS) Act, as amended. The Committee is governed by the
provisions of the Federal Advisory Committee Act, as amended (5
U.S.C. App 2), which sets forth standards for the formation and use
of advisory committees.
Dated: April 18, 2017.
Nicole Greene,
Acting Director, Office on Women's Health.
[FR Doc. 2017-08383 Filed 4-27-17; 8:45 am]
BILLING CODE 4150-42-P